Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: In the phase 3 KEYNOTE-522 study, addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab significantly increased pathologic complete response (pCR) and event-free survival (EFS) vs neoadjuvant chemotherapy in patients with early triple-negative breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masato, Cortés, Javier, Dent, Rebecca, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Denkert, Carsten, Park, Yeon Hee, Im, Seock-Ah, Ahn, Jin-Hee, Mukai, Hirofumi, Huang, Chiun-Sheng, Chen, Shin-Cheh, Kim, Min Hwan, Jia, Liyi, Li, Xin Tong, Tryfonidis, Konstantinos, Karantza, Vassiliki, Iwata, Hiroji, Schmid, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652156/
https://www.ncbi.nlm.nih.gov/pubmed/37966841
http://dx.doi.org/10.1001/jamanetworkopen.2023.42107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652156/
https://www.ncbi.nlm.nih.gov/pubmed/37966841
http://dx.doi.org/10.1001/jamanetworkopen.2023.42107

Ejemplares similares